JP6073230B2 - Ｎｄ２ペプチドおよび神経疾患の治療方法 - Google Patents

Ｎｄ２ペプチドおよび神経疾患の治療方法 Download PDF

Info

Publication number
JP6073230B2
JP6073230B2 JP2013530433A JP2013530433A JP6073230B2 JP 6073230 B2 JP6073230 B2 JP 6073230B2 JP 2013530433 A JP2013530433 A JP 2013530433A JP 2013530433 A JP2013530433 A JP 2013530433A JP 6073230 B2 JP6073230 B2 JP 6073230B2
Authority
JP
Japan
Prior art keywords
peptide
pain
tat
src
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013530433A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014505655A (ja
JP2014505655A5 (enExample
Inventor
マイケル ティミアンスキ，
マイケル ティミアンスキ，
ロンウェン リ，
ロンウェン リ，
ジョナサン デイビッド ガーマン，
ジョナサン デイビッド ガーマン，
Original Assignee
ノノ インコーポレイテッド
ノノ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノノ インコーポレイテッド, ノノ インコーポレイテッド filed Critical ノノ インコーポレイテッド
Publication of JP2014505655A publication Critical patent/JP2014505655A/ja
Publication of JP2014505655A5 publication Critical patent/JP2014505655A5/ja
Application granted granted Critical
Publication of JP6073230B2 publication Critical patent/JP6073230B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y106/00—Oxidoreductases acting on NADH or NADPH (1.6)
    • C12Y106/05—Oxidoreductases acting on NADH or NADPH (1.6) with a quinone or similar compound as acceptor (1.6.5)
    • C12Y106/05003—NADH dehydrogenase (ubiquinone) (1.6.5.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2013530433A 2010-09-28 2011-09-28 Ｎｄ２ペプチドおよび神経疾患の治療方法 Expired - Fee Related JP6073230B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38743910P 2010-09-28 2010-09-28
US61/387,439 2010-09-28
PCT/US2011/053764 WO2012050921A2 (en) 2010-09-28 2011-09-28 Nd2 peptides and methods of treating neurological disease

Publications (3)

Publication Number Publication Date
JP2014505655A JP2014505655A (ja) 2014-03-06
JP2014505655A5 JP2014505655A5 (enExample) 2016-02-25
JP6073230B2 true JP6073230B2 (ja) 2017-02-01

Family

ID=45938878

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013530433A Expired - Fee Related JP6073230B2 (ja) 2010-09-28 2011-09-28 Ｎｄ２ペプチドおよび神経疾患の治療方法

Country Status (15)

Country Link
US (1) US9073976B2 (enExample)
EP (1) EP2621945B1 (enExample)
JP (1) JP6073230B2 (enExample)
KR (1) KR101893473B1 (enExample)
CN (1) CN103282379B (enExample)
AU (1) AU2011314074B2 (enExample)
BR (1) BR112013007557A2 (enExample)
CA (1) CA2812948C (enExample)
DK (1) DK2621945T3 (enExample)
IL (1) IL225464B (enExample)
MX (1) MX343366B (enExample)
RU (1) RU2607033C2 (enExample)
SG (1) SG189104A1 (enExample)
UA (1) UA114592C2 (enExample)
WO (1) WO2012050921A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA123820C2 (uk) * 2014-05-28 2021-06-09 Ноно Інк. Хлоридна сіль пептиду tat-nr2b9c
CN109072242A (zh) * 2016-02-23 2018-12-21 科罗拉多州立大学董事会法人团体 用于治疗神经损伤的基于肽的方法
US11229675B2 (en) * 2016-04-27 2022-01-25 Biocells (Beijing) Biotech Co., Ltd. Therapeutic peptides for excitatory neurotoxicity-related injuries
GB201620611D0 (en) 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
CN112679595B (zh) * 2020-04-10 2022-11-01 南京市儿童医院 脑源肽或融合肽在新生儿缺氧缺血性脑损伤药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2281129T3 (es) * 1997-08-12 2007-09-16 Bristol-Myers Squibb Company Canales de potasio kcnq y procedimientos para su modulacion.
CA2368229A1 (en) * 1999-03-19 2000-09-28 Craig A. Rosen 50 human secreted proteins
NZ527302A (en) * 2001-01-05 2006-10-27 Abgenix Inc Antibodies to insulin-like growth factor I receptor
AU2003262642B2 (en) * 2002-08-14 2010-06-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
EP1551424B1 (en) * 2002-09-04 2015-07-01 Arrowhead Research Corporation Treatment of chronic neuropathic pain by admistration of dsrna
US8003609B2 (en) * 2004-03-30 2011-08-23 The Hospital For Sick Children Method for ameliorating pain by modification of NMDA receptors through inhibition of Src
US7425540B2 (en) * 2004-03-30 2008-09-16 The Hospital For Sick Children Method for modification of NMDA receptors through inhibition of Src
EP1912680B1 (en) * 2005-06-15 2014-11-26 The Ohio State University Research Foundation Her-2 peptides
ES2446292T3 (es) * 2007-03-02 2014-03-07 Nono Inc. Tratamiento del accidente cerebrovascular y otras enfermedades sin inhibir los canales de calcio de tipo N

Also Published As

Publication number Publication date
WO2012050921A2 (en) 2012-04-19
CA2812948A1 (en) 2012-04-19
MX2013003330A (es) 2013-09-26
JP2014505655A (ja) 2014-03-06
IL225464A0 (en) 2013-06-27
CN103282379A (zh) 2013-09-04
MX343366B (es) 2016-11-01
UA114592C2 (uk) 2017-07-10
SG189104A1 (en) 2013-05-31
DK2621945T3 (en) 2018-05-22
RU2013119830A (ru) 2014-11-10
US20140274906A1 (en) 2014-09-18
US9073976B2 (en) 2015-07-07
AU2011314074A1 (en) 2013-05-09
AU2011314074B2 (en) 2015-11-12
CA2812948C (en) 2019-01-22
CN103282379B (zh) 2016-01-06
KR101893473B1 (ko) 2018-08-30
EP2621945B1 (en) 2018-04-11
RU2607033C2 (ru) 2017-01-10
KR20140048070A (ko) 2014-04-23
IL225464B (en) 2018-03-29
BR112013007557A2 (pt) 2021-05-11
EP2621945A2 (en) 2013-08-07
WO2012050921A3 (en) 2012-07-05
EP2621945A4 (en) 2014-05-07

Similar Documents

Publication Publication Date Title
JP5801197B2 (ja) 痛みの治療に関する薬剤及び方法
JP5631595B2 (ja) Ｎ型カルシウムチャネルを阻害せずに卒中および他の疾患を治療する方法
ES2765281T3 (es) Coadministración de un agente unido a un péptido de interiorización con un agente antiinflamatorio
JP6741642B2 (ja) くも膜下出血および虚血の治療法
HUE027216T2 (en) Co-administration of an agent associated with a tat internalizing peptide with an anti-inflammatory agent
US20150147310A1 (en) Targeted enzyme compounds and uses thereof
US9073976B2 (en) ND2 peptides and methods of treating neurological disease
KR20210054542A (ko) 신경 가소성을 유도하기 위한 방법 및 조성물
HK1187931A (en) Nd2 peptides and methods of treating neurological disease
HK1187931B (en) Nd2 peptides and methods of treating neurological disease
WO2016090495A1 (en) TARGETED α-L-IDURONIDASE CONJUGATES AND USES THEREOF

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151130

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20151228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160801

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161206

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170104

R150 Certificate of patent or registration of utility model

Ref document number: 6073230

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees